Characteristics of severe asthma patients included in the French Palomb Cohort
Idioma
EN
Communication dans un congrès
Este ítem está publicado en
ERS International Congress 2023 abstracts, the ERS International Congress 2023, 2023-09-09, Milan. 2023-09-09, vol. 62, n° suppl 67, p. PA4432
Resumen en inglés
Background: The prevalence of severe asthma among asthmatic patients is estimated between 5-10% in France. The aim of this work was to describe clinical features of patients included in the French Severe Asthma Palomb ...Leer más >
Background: The prevalence of severe asthma among asthmatic patients is estimated between 5-10% in France. The aim of this work was to describe clinical features of patients included in the French Severe Asthma Palomb cohort.
Methods: Patients followed in a real-life context by pulmonologists located in 2 regions since 2019. Inclusion criteria: 1) ⩾18 years-old, 2) >6 months follow-up before inclusion for severe asthma, (GINA, 2019) 3) combination of ICS and LABA and anticholinergic, associated with 4) OCS, anti-IgE based treatment, anti-IL5, anti-RIL5, anti-IL4, anti-IL13, thermoplasty.
Results: In January 2023, 214 patients were included. Mean age was 55.1 years old (±16.4). 61.7% were female, 30.0% had a BMI⩾30 (morbid/severe obesity), 29.3% were previous smokers and 4.8% current smokers. 61.4% had an onset of asthma symptoms after the age of 15 and 21.8% had a history of acute severe asthma. 36.8% had dyspnea (mMRC⩾2) and 23.8% had chronic cough (>8 weeks). During the 12 months before inclusion, 25.2% had at least 2 exacerbations (having required a general corticotherapy or an increase in ICS treatment). 29.0% had chronic rhinitis, 22.9% gastro-esophageal reflux disease, 19.2% chronic rhinosinusitis, 14.0% anxiety, 13.6% blood hypertension and 13.1% sleep apnea syndrome. Regarding phenotypes: 46.0% were eosinophilic with allergy and 32.1% were eosinophilic without allergy. 135 patients were already on a biotherapy treatment at inclusion and 26 had a biotherapy introduced at inclusion.
Conclusion: These are preliminary results of an observatory of patients followed with severe asthma in the French medical framework.
Sponsors: Bordeaux University Foundation, AstraZeneca, Chiesi, GSK, Novartis, Sanofi.< Leer menos
Palabras clave en inglés
Asthma management
Environment
Severe asthma
Centros de investigación